Renoprotective effect of angiotensin II receptor antagonists in experimental chronic renal failure

American Journal of Nephrology

Volumn 21, Issue 1, 2001, Pages 78-83

  Eliahou, Haskel ^a,c   Avinoach, Ilana ^a   Shahmurov, Mark ^a   Ben David, Aharon ^b   Shahar, Clarissa ^a   Matas, Zippora ^a   Zimlichman, Reuben ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SHEBA MEDICAL CENTER   (Israel)

^c NONE   (Israel)

Author keywords

Angiotensin II receptor antagonists; Calcium channel blockers; Experimental chronic renal failure; Losartan; Mesangial proliferation; Verapamil

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; LOSARTAN; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG EFFECT; GLOMERULOSCLEROSIS; HISTOPATHOLOGY; MALE; NEPHRECTOMY; NEPHROSCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTECTION; PROTEINURIA; RAT;

ANIMALS; CALCIUM CHANNEL BLOCKERS; KIDNEY FAILURE, CHRONIC; LOSARTAN; MALE; RATS; RATS, INBRED WKY; RECEPTORS, ANGIOTENSIN; VERAPAMIL;

EID: 0035086590     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046225     Document Type: Article

References (26)

1. Control of glomerular hypertension limits glomerular injury in rats with reduced renal mass
2. Short and long term effects of antihypertensive therapy in the diabetic rat
3. The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity
4. Effects of AT-1 receptor antagonist on renal structure and proteinuria in early hypertensive nephrosclerosis
5. Bradykinin causes selective efferent arteriolar dilation during angiotensin I converting enzyme inhibition
6. Discovery of losartan, the first specific non-peptide angiotensin II receptor antagonist
7. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency
8. Optimizing the tolerability/efficacy ratio in hypertension: New clinical findings with angiotensin II antagonists
9. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria
10. Regulation of mesangial cell proliferation
11. Kidney and endocrine system
12. Interleukin 1 and the glomerular mesangium. I. Purification and characterization of a mesangial cell-derived auto-growth factor
13. Production of platelet-derived growth-factor-like protein by rat mesangial cells in culture
14. Recent advances in statins and the kidney
15. Mesangial immune injury, hypertension, and progressive glomerular damage in Dahl rats
16. Candesartan prevents the progression of mesangioproliferative nephritis in rats
17. Candesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats
18. Comparative study of ACE inhibitors and angiotensin II receptor antagonists in interstitial scarring
19. Aldosterone is a major factor in the progression of renal disease
20. Role of aldosterone in the remnant kidney model in the rat
21. Angiotensin receptor antagonists in experimental models of chronic renal failure
22. Chronic renal failure: Management
23. Angiotensin-converting enzyme inhibition and renal protection: An assessment of implications for therapy
24. Novel strategies to retard renal disease progression: Combining ACE inhibition with endothelin receptor blocking?
25. Understanding the nature of renal disease progression